Beta Blockers and Gout Risk
Calcium channel blockers and losartan are the preferred antihypertensive agents for patients with gout or at risk for gout, as beta blockers are associated with increased serum uric acid levels and gout risk.
Evidence-Based Recommendation
The most recent EULAR gout management guidelines 1 explicitly recommend that when gout occurs in patients requiring antihypertensive therapy, clinicians should "consider losartan or calcium channel blockers" for hypertension management. This recommendation is reinforced by the 2006 EULAR guidelines 2 which state that when gout associates with antihypertensive therapy, treatment regimens should avoid thiazides and consider losartan due to its modest uricosuric effects.
Why Beta Blockers Should Be Avoided
Beta blockers consistently increase serum uric acid levels and gout risk across multiple studies:
A 2017 study in African Americans with chronic kidney disease 3 found that metoprolol increased serum uric acid by 0.3 mg/dL at 12 months and significantly increased the odds of gout-related medication use (OR: 1.62; 95% CI: 1.03-2.54).
A large UK population-based case-control study 4 demonstrated that beta blockers increased gout risk with a multivariate relative risk of 1.48 (95% CI: 1.40-1.57) among hypertensive patients.
A 2016 cross-sectional study 5 confirmed that patients treated with beta blockers had significantly higher serum uric acid levels, with multiple regression analysis showing beta blockers significantly contributed to hyperuricemia.
Preferred Alternatives
If you need to prescribe an antihypertensive agent in a patient with gout or hyperuricemia, choose in this order:
Losartan (ARB with uricosuric properties) - Associated with 19% lower gout risk (RR: 0.81; 95% CI: 0.70-0.94) 4. The 2020 ACR guidelines 6 conditionally recommend choosing losartan preferentially when feasible.
Calcium channel blockers - Associated with 13% lower gout risk (RR: 0.87; 95% CI: 0.82-0.93) 4, with longer duration of use showing greater protective effect (RR: 0.75 for ≥2 years use).
ACE inhibitors (except in combination with other RAAS blockers) - While the 2015 UK study 4 showed a modest increased risk (RR: 1.24), the 2017 AASK trial 3 found ramipril had no effect on serum uric acid, making it neutral rather than harmful.
Clinical Algorithm
When managing hypertension in patients with gout:
- Stop beta blockers if clinically feasible and switch to losartan or calcium channel blockers
- If beta blocker cannot be stopped (e.g., post-MI, heart failure with reduced ejection fraction), ensure patient is on optimal urate-lowering therapy with target serum uric acid <6 mg/dL
- Monitor serum uric acid levels more frequently (every 3-6 months) in patients who must remain on beta blockers
- Avoid combining beta blockers with diuretics in gout patients, as this creates additive hyperuricemic effects
Important Caveats
The 2017-2018 ACC/AHA hypertension guidelines 7, 8, 9 note that beta blockers are not recommended as first-line agents for hypertension without compelling indications (such as heart failure, post-MI, or coronary artery disease). When beta blockers are indicated for these conditions, the cardiovascular benefits typically outweigh gout risks, but aggressive urate-lowering therapy becomes essential.
The evidence is clear: among beta blockers, none are "safe" for gout - the mechanism appears to be a class effect related to reduced renal uric acid clearance. While one older study 10 suggested timolol didn't affect uric acid handling in normotensive subjects, this has been contradicted by larger, more recent studies in hypertensive populations where beta blockers are actually used clinically.